The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial

John R. Attia1,2 - Elizabeth Holliday3 - Natasha Weaver3 - Roseanne Peel3 - Kerry C. Fleming3 - Alexis Hure4 - John Wiggers3,5 - Mark McEvoy3,6 - Andrew Searles7 - Penny Reeves7 - Priyanga Ranasinghe8 - Ranil Jayawardena8 - Samir Samman9 - Judy Luu10 - Chris Rissel11 - Shamasunder Acharya12

Original Article

Acta Diabetologica (2022) 59:965–975
https://doi.org/10.1007/s00592-022-01888-x

Received: 3 March 2022 / Accepted: 30 March 2022 / Published online: 22 April 2022
© The Author(s) 2022

Abstract

Aims The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults.

Methods We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD) Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N=98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse.

Results The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, \( p=0.78 \)) for HbA1c and 0.17 (−0.07, 0.42; \( p=0.17 \)) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%).

Conclusion We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient.

Trial registration Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268. Registered on 6 July 2018.

Keywords Prediabetes · Zinc supplementation · Randomized controlled trial · Prevention · Diabetes prevention · General practice · Get healthy · Adults · Australia

Abbreviations

RCT Randomised controlled trial
ZIPPeD Zinc in preventing the progression of pre-diabetes
BMI Body mass index
HbA1c Haemoglobin A1c
FBG Fasting blood glucose
HOMA 2 Homeostasis model assessment 2
REDCap Research electronic data capture
CI, SD, IQR, OR Confidence interval, standard deviation, Interquartile range, odds ratio
HOMA 2 Homeostasis model assessment 2
HNELHD Hunter New England local health district
TRGS Translational research grant scheme
HREC Human research ethics committee
NSW New South Wales

Managed by Antonio Secchi.

* John R. Attia
john.attia@newcastle.edu.au

Extended author information available on the last page of the article

© Springer
Background and aims

As of 2019, 9.3% of the world population (463 million people aged 20–79 years) had a diagnosis of diabetes; this is projected to increase to 758 million by 2030 and 700 million by 2045 [1]. The global cost to health systems in 2019 was $760 billion and is projected to increase to $825 billion (USD) by 2030, and $845 billion by 2045 [1]. It is estimated that 90–95% of all cases of diabetes are type 2 [2] and, given that the natural history of this chronic condition is to first pass through a stage of impaired glucose tolerance (pre-diabetes), there is an opportunity to intervene early, thereby delaying progression to diabetes, and avoiding later consequences including retinal disease, kidney disease, peripheral vascular disease, and cardiovascular disease [3, 4].

Type 2 Diabetes is largely preventable by improving lifestyle factors including nutrition, physical activity and maintenance of normal body weight; these measures should obviously be targeted at the entire population, not only for the prevention of diabetes but also other chronic diseases [5]. However, programs that target these behaviours take time to show an effect and sustained health behaviour change is slow. Therefore, cheap and simple interventions that can prevent or at least delay the progression of disease while these health behaviour interventions are adopted would be a useful adjunct in our preventive measures.

We previously outlined the various roles of zinc in glucose handling [6], including being involved in the synthesis, storage, and secretion of insulin, and moderating inflammatory cytokines [7–10]. Oxidative stress is relatively common in diabetes, and zinc also has antioxidant properties, acting as a cofactor for the superoxide dismutase enzyme that detoxifies reactive oxygen species [11]. Genome-wide association studies of Type 2 Diabetes have also identified an association with a genetic variant in the SLC30A8 gene, which encodes a zinc transporter, ZnT8 [12]. The associated genetic variant causes an amino acid change in the transporter which increases disease risk by an estimated 17% per risk allele [13].

Zinc supplementation studies in animal models of diabetes over the last 35 years have been largely positive and support the use of supplemental zinc to improve glucose handling [6, 14–17]. Meta-analyses of zinc supplementation in humans have also suggested favourable effects on fasting blood glucose (FBG) and Haemoglobin A1c (HbA1c) [18, 19]. The majority of the trials identified by these two reviews, however, are small (20–30 participants per group), short-term (up to 6–12 weeks of supplementation), and in low- and middle-income countries (Iran, Iraq, India, Sri Lanka) where diets may be deficient in zinc.

Perhaps the most compelling evidence for the role of supplemental zinc in preventing the progression of pre-diabetes is the RCT conducted by Ranasinghe et al. [20] in Sri Lanka (SLCTR/2012/010). Over 12 months, 20 mg of daily zinc supplementation significantly improved FBG, Oral Glucose Tolerance Test (OGTT), and Homeostasis Model Assessment (HOMA)-calculated insulin resistance and beta-cell function compared to the placebo group. Furthermore, the progression to overt diabetes was reduced from 25% in the placebo group to 11% in the zinc group ($p=0.016$) [6].

We set out to test whether zinc supplementation was effective in a pre-diabetic population with a Western diet, trialing 30 mg/day supplemental zinc for 12 months, with primary endpoints of HbA1c and FBG at 6 months.

Methods

We conducted a randomised, double-blind, placebo-controlled trial in a pre-diabetic population aged 40–70 years; zinc supplementation (30 mg/daily) or placebo was continued over 12 months, with blood samples taken at baseline, 1, 6 and 12 months for FBG, HbA1c, and insulin levels for calculation of HOMA parameters. The two primary outcomes were HbA1c and FBG, each measured after 6 months of treatment. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD Study). The protocol has been previously published (Trial registration: ACTRN12618001120268) with methods briefly described below [6].

Recruitment

The study was conducted in Newcastle (NSW, Australia) through the Hunter Diabetes Alliance, which brings together hospital-based diabetes specialists and general practitioners in the Hunter New England local health district to improve diabetes care, using a case conferencing model of continuing professional development [6, 21]. Practices that were part of the Alliance were invited to participate in this study. A research nurse worked with each practice nurse to identify pre-diabetic patients using a two-fold approach:

- Review of practice records over the previous year for HbA1c or FBG values in the pre-diabetic range (5.7–6.4% (39–46 mmols/mol) and 6.1–6.9 mmol/l respectively)
- Screening of patients in the waiting room using the AUS-DIAB questionnaire (AUSDRISK) [22] and a point of care HbA1c.

Eligibility criteria

- Age = 40–70 years


- Pre-diabetes as defined by HbA1c of 5.7–6.4%, (39–46 mmols/mol)
- Body Mass Index (BMI) ≥ 27 kg/m²

**Exclusion criteria**

- Taking any other vitamin or mineral supplementation containing zinc
- Currently using weight loss medication
- History of Diabetes Mellitus.
- Pregnancy or lactation for women of child-bearing age
- Impaired hepatic (AST or ALT > three times the upper limit of normal) or renal function (Stage 3 chronic kidney disease)
- Taking pharmacological agents that may interfere with the intervention (for example, diuretics, metformin, and complementary medicines)
- Past history of pancreatitis
- Current cancer under treatment, terminal cancer, terminal illness

**Baseline visit and randomization**

Patients meeting the above criteria were invited to participate. Those giving informed consent had their height, weight, and hip circumference measured in the practice and were provided with pathology forms to check their baseline FBG, HbA1c, and insulin levels, as well as lipid profile at their local public pathology provider, with whom the team had a research agreement. A baseline questionnaire captured socio-demographic information, smoking and alcohol consumption, ethnicity, self-reported medical history, medications, and exercise. Diet quality was captured using a web-based food frequency questionnaire (FFQ) [23]. Every participant was also referred to the Get Healthy Information and Coaching Service, run by the New South Wales state health department. This free Service provides up to 13 telephone calls over 6 months from allied health professionals who provide personalised health information and support participants to achieve a better lifestyle focusing on diet, physical activity, smoking cessation and alcohol reduction [24].

Randomisation codes were generated by an independent statistical team (The Clinical Research Design, Information Technology and Statistical Support (CReDITSS) unit at the Hunter Medical Research Institute) using permuted blocks of size 4 or 6, stratified by General Practitioner (GP) practice. These were entered into a Research Electronic Data Capture (REDCap) database [25] and assigned sequentially by the research manager (independent of the study nurse).

**Intervention**

On completion of all the baseline measures, participants were randomised to the treatment or placebo group. Active drug was a daily capsule containing 30 mg elemental zinc gluconate, based on the dose from previous studies [2], our pilot data, and the mean dose in the meta-analysis [18] (donated by Blackmores Ltd, Australia). The placebo capsule, containing cellulose, was identical in appearance, shape, and colour to the zinc capsule (also donated by Blackmores Ltd. Australia). All study participants were sent a 3-month supply, with instructions to take the study capsule daily with breakfast. Every quarter thereafter, participants were sent a new 3-month supply with instructions to return a side-effect questionnaire and any remaining capsules via a postage-paid envelope; adherence was assessed by the study nurse using pill counts of the returned bottles and by calculating the percentage of total tablets taken during the measured interval.

**Follow-up**

Participants were followed up every 3 months by mail with a new supply of capsules and an adverse event form to complete. A reply-paid padded envelope was included for the return of old pill bottles and the completed adverse event report. Pathology request forms were mailed out at 1-, 6- and 12-month timepoints. Reminders for baseline and follow-up blood tests and other incomplete tasks (surveys) were sent by SMS, postcard, phone call or email as required. At the final 12-month timepoint, blood was collected and analysed for lipid profile. Height, weight and waist circumference were measured again at 12 months at the general practice, and the web based FFQ was re-administered.

**Outcome measures**

**Primary outcome measures**

The two primary outcomes were HbA1c and FBG at 12 months.

**Secondary measures**

The secondary outcomes were:

- HbA1c and FBG at 1 month and 6 months
- HOMA parameters of beta cell function, insulin resistance, and insulin sensitivity at 1 month, 6 months and 12 months (calculated using the Homeostasis Model Assessment 2 (HOMA2)) calculator University of Oxford:
  
  http://www.dtu.ox.ac.uk/homacalculator/index.php).
• Lipid profile at 1 month, 6 months and 12 months
• Weight, BMI, waist circumference and blood pressure at 12 months
• Progression to diabetes at 12 months (as defined by HbA1c $\geq 6.5\%$, (> 48mmols/mol) or fasting blood glucose $> 7$ mmol/l)
• Adherence (defined as % of total required capsules taken)

**Measurement of biochemical variables**

Blood samples were collected from participants and analysed as contracted by Pathology North, a NATA-accredited public pathology provider associated with outlets across the study catchment.

**Sample size**

The sample size was based on the primary or secondary endpoint with the smallest assumed effect size: insulin sensitivity (IS). We estimated that with an assumed mean difference in IS of 0.3 (with SD of 0.7, equal to Cohen’s d of 0.4) between the intervention and control groups, we would need 164 participants per group to reject the null hypothesis with probability (power) 0.9 and type I error probability (α) of 0.01. Allowing up to 20% loss to follow-up over 1 year, we aimed to recruit a total of 410 participants. Unfortunately, COVID-19 restrictions curtailed our ability to visit GP practices and recruit face to face. The study was ended prematurely with 98 participants randomised. These participants were all followed up for 1 year.

**Statistical analyses**

Distributions of participant baseline characteristics were summarised by group using mean with standard deviation (SD), median with interquartile range (Q1, Q3) or frequency with percent, as appropriate.

For primary outcomes, distributions were summarised using mean (SD) for each drug group at baseline, 1 month, 6 months and 12 months. Treatment effects were estimated using a linear mixed model including outcomes measured at all three follow-up timepoints. Models included a random intercept for individual (to account for repeated measures on participants) and fixed effects for group, time (categorical), and the interaction term of group x time. Models were adjusted for sex and the baseline value of the outcome. Group differences were reported as the baseline-adjusted mean group difference at 1 month, 6 months and 12 months with 95% confidence interval (CI) and $p$-value. A type III $p$-value for the interaction term was also presented. For each of the two primary endpoints (6 months), two-sided statistical significance was evaluated at the 0.025 level. A scatter plot of fitted values versus studentized residuals and a needle plot of Cook’s distances was used to check for influential outliers.

In a secondary analysis of the primary outcomes, a spaghetti plot (participant outcome values versus continuous time) was used to assess linearity of the time effect, which was judged as fair. Models were then refit including time as a continuous predictor, assuming linearity, and the group effect was estimated as a difference in slopes (Drug B vs. Drug A) with 95% CI.

For secondary outcomes measured at baseline, 1 month, 6 months and 12 months, analyses were performed as for the primary outcomes, with statistical significance declared at the 0.05 level. For secondary outcomes measured at baseline and 12 months only (body weight, BMI, waist circumference, blood pressure), baseline-adjusted group differences at 12 months were estimated using a linear model, adjusted for baseline values, with no random effect or interaction term.

Analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA) using the MIXED procedure with REML estimation algorithm. LSMEANS statements were used to estimate the mean differences and their CIs.

**Results**

We identified 1212 people with pre-diabetes across 10 practices, of which 961 were non-eligible or non-contactable; 251 were approached, of which 143 consented but only 98 completed baseline questionnaires and were subsequently randomised. Of the remaining 45, 3 were found to be diabetic and hence ineligible and 42 never completed baseline questionnaires or bloods and so did not progress to randomisation; the consort flow diagram summarising recruitment is shown in Fig. 1.

These participants consisted of 44 males and 54 females ($n = 98$, 55% female); age was slightly left-skewed with mean (SD) 60.8 (7.5) and median (IQR) 62.9 (56.6, 67.0). Mean (SD) BMI was 34.1 (6.3) and mean waist circumference was largely above the healthy recommended limit of 88 cm in women and 102 in men. Around half of participants had never smoked ($n = 52$, 53%), and around half consumed alcohol within recommended levels.

The study participant characteristics were well balanced across the 2 arms of the study (see Table 1).

The baseline-adjusted mean group difference, expressed as treatment-placebo (95% CI) for HbA1c at 6 months was $-0.02 (-0.14, 0.11)$ and was not statistically significant ($p = 0.79$). The baseline-adjusted mean group difference in FBG at 6 months was also not statistically significant, at 0.17 ($-0.07, 0.42; p = 0.17$). The type III $p$-value indicated no global difference in HbA1c across the three follow-up timepoints ($p = 0.42$). The type III $p$-value for FBG was 0.034,
Screening by Diabetes Alliance for Pre-Diabetes in Men and Women aged 40-70 years

Assessed for Eligibility (n=1212)

Excluded
- Ineligible or did not respond (n=961)
- Did not consent (n=108)

Informed Consent given (n=143)

Excluded
- Withdrawn prior to randomisation (n=42)
- Ineligible - Diagnosis of diabetes (n=3)

Randomised (n=98)

Allocated to intervention/active (n=48)
- Received allocated intervention (n=48)

Allocated to control (n=50)
- Received control (n=50)

Follow-Up (6 months)

Lost to follow-up (0-6 months)
- Diabetes (n=1)
- No response or withdrawn (n=7)

Lost to follow-up (6-12 months)
- Diabetes (n=2)
- No response or withdrawn (n=3)

Analysis

Analysed (n=48)
- Lost to follow-up (0-12 months)
- Developed diabetes (n=3)
- Lost to follow-up (n=15)

Analysed (n=50)
- Lost to follow-up (0-12 months)
- Developed diabetes (n=3)
- Lost to follow-up (n=10)

Fig. 1 Zinc In Preventing the Progression of pre-Diabetes Study (ZIPPeD Study) Consort Flow Diagram
but group differences did not show a consistent direction of effect across timepoints (see Table 2).

A small number of the group differences in secondary outcomes were statistically significantly at the 0.05 level, either evaluated at single timepoints, or across all follow-up timepoints (type III \( p \)-value) but these were not in any consistent directions and are likely due to type I error. Table 3 shows effect estimates for HOMA-derived parameters of beta-cell function, insulin resistance, insulin sensitivity and lipid parameters.

Table 4 shows estimates for outcomes of metabolic health, including weight, BMI, waist circumference and blood pressure.

Zinc was generally well tolerated and adherence was high; percentage of all doses taken was 88% (± 10%) for the zinc group vs 86% (± 12%) for the placebo group; this translates into 66% of the placebo group having at least 80% compliance versus 63% in the active group. Not all participants completed the side effect questionnaire, but for those who did dry mouth, heartburn, indigestion, stomach pain, diarrhoea, cramping were the most common symptoms and were equally distributed across both groups. There were no severe adverse events. (See Supplemental Table S1).

A sensitivity analysis assessing whether greater adherence with the zinc capsules was associated with better FBG or HbA1c using linear regression did not find any significant effect. Each 1% increase in adherence was associated with an estimated 0.55% (95% CI –0.63–1.73, \( p = 0.35 \)) increase in HbA1c and a 0.94 mmol/mol (95% CI –1.36–3.24, \( p = 0.41 \)) increase in FBG.
### Table 2  Analysis of primary outcomes

| Outcomes                  | Time    | Treatment group | Placebo Mean (SD) | Active Mean (SD) | Mean difference (95% CI) | P-value | Type III P-value |
|---------------------------|---------|-----------------|-------------------|------------------|--------------------------|---------|-----------------|
| **Primary outcomes**      |         |                 |                   |                  |                          |         |                 |
| HbA1c                     | Baseline| 5.90 (0.20)     | 5.87 (0.19)       |                  |                          |         |                 |
|                           | 1 month | 5.85 (0.35)     | 5.82 (0.25)       | −0.00 (−0.12, 0.12) | 0.9969                  |         |                 |
|                           | 6 month | 5.86 (0.24)     | 5.82 (0.29)       | −0.02 (−0.14, 0.11) | 0.7871                  |         |                 |
|                           | **12 month** | **5.96 (0.30)** | **5.84 (0.29)** | **−0.06 (−0.19, 0.06)** | **0.3214** | **0.4167** |         |                 |
| Fasting blood glucose level | Baseline| 5.88 (0.84)     | 5.81 (0.71)       |                  |                          |         |                 |
|                           | 1 month | 5.67 (0.63)     | 5.66 (0.68)       | 0.04 (−0.19, 0.26) | 0.7540                  |         |                 |
|                           | 6 month | 5.61 (0.65)     | 5.75 (0.71)       | 0.17 (−0.07, 0.42) | 0.1691                  |         |                 |
|                           | **12 month** | **5.89 (0.66)** | **5.59 (0.68)** | **−0.19 (−0.44, 0.06)** | **0.1386** | **0.0336** |         |                 |

Bold values indicate the main outcome timeframe.

### Table 3  Analysis of secondary outcomes (HOMA2 parameters and laboratory measurements)

| Outcomes                  | Time    | Treatment group | Placebo Mean (SD) | Active Mean (SD) | Mean difference (95% CI) | P-value | Type III P-value |
|---------------------------|---------|-----------------|-------------------|------------------|--------------------------|---------|-----------------|
| **Beta cell function (%B)** | Baseline| 105.01 (36.81) | 100.37 (35.38)    |                  |                          |         |                 |
|                           | 1 month | 113.08 (39.86) | 107.48 (34.73)    | −5.74 (−16.71, 5.23) | 0.3028                  |         |                 |
|                           | 6 month | 114.47 (44.71) | 102.43 (30.09)    | −10.01 (−21.64, 1.63) | 0.0913                  |         |                 |
|                           | **12 month** | **105.83 (36.60)** | **101.40 (29.04)** | **−2.71 (−14.56, 9.14)** | **0.6521** | **0.4306** |         |                 |
| **Insulin sensitivity (%S)** | Baseline| 69.82 (44.30) | 76.22 (44.39)     |                  |                          |         |                 |
|                           | 1 month | 67.43 (37.03) | 74.05 (44.35)     | 6.96 (−3.51, 17.43) | 0.1910                  |         |                 |
|                           | 6 month | 74.07 (52.00) | 70.89 (34.51)     | −1.30 (−12.53, 9.93) | 0.8195                  |         |                 |
|                           | **12 month** | **65.71 (34.84)** | **77.70 (34.58)** | **12.17 (6.68, 23.65)** | **0.0381** | **0.0930** |         |                 |
| **Insulin resistance (IR)** | Baseline| 1.89 (0.91)   | 1.74 (0.94)       |                  |                          |         |                 |
|                           | 1 month | 1.91 (1.04)   | 1.76 (0.83)       | −0.14 (−0.37, 0.10) | 0.2597                  |         |                 |
|                           | 6 month | 1.90 (1.08)   | 1.73 (0.79)       | −0.11 (−0.36, 0.15) | 0.4013                  |         |                 |
|                           | **12 month** | **1.96 (1.02)** | **1.58 (0.74)** | **−0.26 (−0.52, −0.00)** | **0.0463** | **0.4923** |         |                 |
| **Total cholesterol (mmol/l)** | Baseline| 5.13 (1.04)   | 5.14 (1.09)       |                  |                          |         |                 |
|                           | 1 month | 5.06 (1.00)   | 5.10 (1.23)       | 0.11 (−0.19, 0.41) | 0.4764                  |         |                 |
|                           | 6 month | 4.98 (1.00)   | 5.35 (1.37)       | 0.26 (−0.05, 0.58) | 0.1042                  |         |                 |
|                           | **12 month** | **4.87 (1.08)** | **5.12 (1.41)** | **0.10 (−0.22, 0.43)** | **0.5367** | **0.5667** |         |                 |
| **LDL (mmol/l)**           | Baseline| 3.08 (0.98)   | 3.01 (0.88)       |                  |                          |         |                 |
|                           | 1 month | 2.97 (0.90)   | 3.09 (1.03)       | 0.14 (−0.12, 0.41) | 0.2861                  |         |                 |
|                           | 6 month | 3.02 (0.97)   | 3.25 (1.16)       | 0.12 (−0.16, 0.40) | 0.3894                  |         |                 |
|                           | **12 month** | **2.90 (0.97)** | **3.04 (1.20)** | **0.06 (−0.23, 0.35)** | **0.6797** | **0.8359** |         |                 |
| **HDL (mmol/l)**           | Baseline| 1.28 (0.34)   | 1.29 (0.36)       |                  |                          |         |                 |
|                           | 1 month | 1.28 (0.32)   | 1.25 (0.33)       | −0.03 (−0.16, 0.11) | 0.6917                  |         |                 |
|                           | 6 month | 1.42 (0.70)   | 1.30 (0.36)       | −0.15 (−0.30, −0.00) | 0.0446                  |         |                 |
|                           | **12 month** | **1.26 (0.30)** | **1.32 (0.35)** | **0.01 (−0.14, 0.16)** | **0.9158** | **0.2546** |         |                 |
| **Triglycerides (mmol/l)** | Baseline| 1.74 (0.77)   | 1.86 (1.07)       |                  |                          |         |                 |
|                           | 1 month | 1.70 (0.72)   | 1.69 (0.72)       | −0.05 (−0.31, 0.20) | 0.6851                  |         |                 |
|                           | 6 month | 1.55 (0.78)   | 1.90 (0.86)       | 0.29 (0.02, 0.56)  | 0.0358                  |         |                 |
|                           | **12 month** | **1.67 (0.83)** | **1.70 (0.81)** | **0.04 (−0.23, 0.31)** | **0.7774** | **0.0158** |         |                 |
Discussion

We did not find any evidence that zinc supplementation in an Australian cohort of pre-diabetic individuals over the course of 12 months had any effect on glucose handling, whether measured by FBG, HbA1c or HOMA parameters; there was also no difference on any metabolic measures, whether measured by lipid profile, blood pressure, BMI, or waist circumference. How can we reconcile these results with the body of literature demonstrating an effect of zinc?

Although recruitment was ceased prematurely due to COVID-19, our study still represents one of the largest RCTs in this area with the longest follow-up, and we do not believe that type II error, i.e. lack of power, is a likely explanation for our negative result. The meta-analyses [19, 20, 26] indicated effect sizes of 0.5–0.6% reduction in HbA1c and 0.8–1 mmol/L reduction in FBG. Post hoc power calculations indicate that, with our sample size, we had over 95% power to detect effects of this magnitude. It is still possible that there is an effect of zinc but that it is markedly smaller in our Western population.

Three different meta-analyses all indicated a beneficial effect of zinc on glucose handling [18, 26, 27]. It is always possible that these differences are due to methodological deficits. In general, the studies included in these reviews are small, e.g. 12–40 people per arm, the heterogeneity of the pooled estimates is high, e.g. > 90%, and they did not check for publication bias, for example, using funnel plots or Egger’s test.

Although the studies included in these three reviews were different, there was a large body of overlap and a substantial number of these studies were conducted in non-Western countries, e.g. Iran, Iraq, India, Sri Lanka, where diets differ substantially. It is thus possible that zinc exerts a beneficial effect only in the setting of a zinc deficient diet. Given that zinc is found in the highest quantities in seafood (oysters and crab), meat (especially beef) and seeds/nuts (almonds, pepitas) [28] it is possible that an effect of zinc was seen in countries where vegetarian diets are more prominent, and that the effect of zinc was not seen in our Australian population due to a higher intake of meat [28].

Capdor et al. [27] pooled studies across normoglycaemic and dysglycemic populations, including metabolic syndrome, type 1 and type 2 diabetes, whereas Jayawardena and Wang limited the selection criteria more strictly to populations with diabetes. Another explanation is that diabetes leads to renal pathology and subsequently to loss of zinc through the kidneys; hence, zinc replacement in diabetic patients addresses a physiological deficiency and improves glucose handling. Previous studies have confirmed increased zinc loss in diabetes [29]; it appears that it is not necessary to have overt nephropathy for this to happen but that the presence of microalbuminuria is sufficient [30]. It is possible that the positive results from diabetes subjects skewed the overall results in the Capdor meta-analysis? [27]. Nevertheless, the RCT of zinc in pre-diabetics by Ranasinghe et al. [20] is compelling in indicating that zinc does have a beneficial effect even before microalbuminuria is present, and likely points to the adequacy of the background diet as the key determinant of whether supplemental zinc influences glucose handling.

Another possibility is that the form of supplementation we used was inadequate. The majority of previous studies used zinc sulphate whereas we used zinc gluconate. Our choice was influenced by the greater tolerability of the gluconate salt and the greater bioavailability [31].

What then do we make of studies in Western populations that also show a beneficial effect? The majority of randomized trials included across the 3 meta-analyses from Western countries (e.g. Australia, France, USA) do not show

Table 4 Analysis of secondary outcomes (physical measurements)

| Outcomes                  | Treatment group | Active—placebo | P-value (treatment) |
|---------------------------|-----------------|----------------|--------------------|
|                           | Timepoint       | Placebo        | Active             | Mean difference (95% CI) |
| Body weight kilograms     | Baseline        | 94.53 (20.07)  | 95.60 (17.00)      | −0.60 (−2.51, 1.31)     | 0.5330 |
|                           | 12 month        | 93.86 (20.73)  | 92.28 (16.16)      | −0.60 (−2.51, 1.31)     | 0.5330 |
| BMI (Body Mass Index) kg/m²| Baseline        | 33.58 (5.72)   | 34.57 (6.80)       | −1.00 (−2.51, 1.31)     | 0.8661 |
|                           | 12 month        | 32.85 (6.75)   | 32.74 (5.17)       | −0.07 (−0.87, 0.73)     | 0.8661 |
| Waist Circumference (cm)  | Baseline        | 110.13 (14.95) | 109.80 (11.96)     | −0.33 (−2.51, 1.31)     | 0.8661 |
|                           | 12 month        | 108.57 (16.58) | 106.53 (10.60)     | −0.99 (−4.32, 2.33)     | 0.5528 |
| Systolic blood pressure (mmHg) | Baseline | 134.52 (16.28) | 133.10 (16.97) | −1.42 (−4.32, 2.33) | 0.5741 |
|                           | 12 month        | 133.23 (14.90) | 132.42 (13.57)     | −0.80 (−4.32, 2.33)     | 0.5741 |
| Diastolic blood pressure (mmHg) | Baseline | 82.26 (9.16)   | 83.38 (9.35)       | −1.00 (−2.51, 1.31)     | 0.8369 |
|                           | 12 month        | 78.09 (8.87)   | 79.55 (8.19)       | −0.46 (−4.18, 3.40)     | 0.8369 |
 favourable point estimates; it is only previous observational studies that show this. For example, our previous study looking at a community-based cohort of older Australians found that higher serum zinc (by 1 quartile) was associated with increased insulin sensitivity (by one decile) within the pre-diabetic group, even after adjusting for a wide range of potential confounders [32]. We also analysed data from the ‘Australian Longitudinal Study of Women’s Health’, a cohort of over 40,000 women across Australia, to determine whether dietary zinc was associated with risk of Type 2 Diabetes. In the stratum of middle-aged women, we found that those in the highest quintile of total dietary zinc intake had significantly lower risk of Type 2 Diabetes compared to the lowest quintile (OR = 0.50, 95% C.I. 0.32–0.77) [33]. In hindsight, perhaps the best interpretation of these results is that there was residual confounding, and that zinc (in the blood or diet) is a marker of a healthier diet and/or lifestyle that reduces the chance of developing diabetes but is not the key element on which to intervene in a Western population. This is further supported by the fact that an identical RCT protocol to the one in this study was tested in a Bangladeshi population and did show beneficial effects of zinc [34].

Conclusions

Our study does carry some caveats. We did not reach our target sample size and the total number of participants recruited was modest relative to our recruitment target. Nevertheless, the methods were rigorous, and the randomisation was effective, leading to well-balanced groups. Almost 70% of participants gave complete data and adherence with tablets was over 85%, with zinc being very well tolerated. While a previous RCT indicated a positive effect of zinc in prediabetes [20], our results do not support this practice; the discrepancy may be related to whether the target population is zinc replete or zinc deficient.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00592-022-01888-x.

Acknowledgements  We would like to thank the study participants, the General Practitioners and Practice staff, the Diabetes Alliance team, the Public Health Network and The Get Healthy Information and Coaching Service.

Author contributions  JA is the Chief Investigator and Sponsor for the study and prepared the draft manuscript. EH is the protocol senior statistician and supervised the statistical analyses. NW performed the statistical analyses. RP is the ZIPPeD Study Coordinator. KF is the Diabetes Alliance nurse. AH is the protocol dietitian. JW is the protocol expert in Population health, translational research and implementation. MM is the protocol epidemiologist. AS, PR are the protocol economists. PR, RJ and SS are members of the research steering committee. SA, JL are diabetes experts and recruitment facilitators. CR is the project lead for the “Get Healthy Information and Coaching Service” and facilitator for this service. All authors read, contributed to and approved the final manuscript. Laureate Professor John Attia is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding  Open Access funding enabled and organized by CAUL and its Member Institutions. This work is jointly supported by the New South Wales (NSW) Ministry of Health Translational Research Grant Scheme (TRGS) for the overall funding of the ZIPPeD study (H18/31636) and Hunter New England Local Health District (HNELHD) integrated care funding allocated by the NSW Ministry Of Health. Blackmores Limited provided the zinc and placebo supplements and funds to support mailing costs. The study funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Availability of data and materials  The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest  All authors declare that they have no conflict of interest.

Ethics Approval  The project was approved by the Hunter New England Human Research Ethics Committee (HREC), a lead HREC (approval ID: 2019/ETH01226) and registered with the University of Newcastle’s HREC (approval ID: H-2018-0302). The reported investigations have been carried out in accordance with the Declaration of Helsinki as revised in 2008.

Informed consent  Informed consent was obtained from all participants.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. International Diabetes Federation (IDF). IDF Diabetes Atlas 2019 [9th Edition]:Available from: https://www.diabetesatlas.org/en/.

2. Bartlett HE, Eperjesi F (2008) Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic Physiol Opt 28(6):503–523

3. Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30(3):753–759
4. Twigg S, Kamp M, Davis T, Neylon E, Flack J (2007) Prediabetes: a position statement from the Australian diabetes society and Australian diabetes educators association. Med J Aust 186(9):461
5. Tuomilehto J, Lindström J, Eriksson J et al (2001) Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
6. Peel R, Hure A, Wiggers J et al (2019) Zinc in preventing the progression of pre-diabetes (ZIPPeD Study)–study protocol for a randomised placebo-controlled trial in Australia. Trials 20(1):219
7. Huang XF, Arvan P (1995) Intracellular transport of proinsulin in pancreatic β-Cells: structural maturation probed by disulfide accessibility. J Biol Chem 270(35):20417–20423
8. Jansen J, Karges W, Rink L (2009) Zinc and diabetes–clinical links and molecular mechanisms. J Nutritional Biochem 20(6):399–417
9. Chausmer AB (1998) Zinc, insulin and diabetes. J Am Coll Nutr 17(2):109–115
10. Brender JR, Hartman K, Nanga RPR et al (2018) Zinc supplementation for impaired glucose regulation and type 2 diabetes. World J Diabetes 6(2):333–337
11. Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445(7130):881–885
12. Shan Z, Bao W, Zhang Y et al (2014) Interactions between zinc transporter-8 gene (SLC30A8) and plasma zinc concentrations associated with pancreatic β-cell function and insulin sensitivity in pre-diabetic and normal individuals? Findings from the Australian longitudinal hunter community study. PLoS ONE 9(1):1–7
13. Vashum KP, McEvoy M, Shi Z et al (2013) Is dietary zinc protective for type 2 diabetes? Results from the Australian longitudinal study on women’s health. BMC Endo Dis 13(1):40
14. Islam MR, Attia J, Ali L et al (2016) Zinc supplementation for improving glucose handling in pre-diabetes: a double blind randomized placebo controlled pilot study. Diabetes Res Clin Pract 115:39–46

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

John R. Attia1,2 · Elizabeth Holliday3 · Natasha Weaver3 · Roseanne Peel1 · Kerry C. Fleming3 · Alexis Hure4 · John Wiggers3,5 · Mark McEvoy3,6 · Andrew Searles7 · Penny Reeves7 · Priyanga Ranasinghe8 · Ranil Jayawardena8 · Samir Samman9 · Judy Luu10 · Chris Rissel11 · Shamasunder Acharya12

1 School of Medicine and Public Health, University of Newcastle, New Lambton Heights, Australia
2 Division of Medicine, Hunter New England Local Health District, New Lambton Heights, Australia
3 School of Medicine and Public Health, University of Newcastle, New Lambton Heights, Australia
4 Diabetes Service and Diabetes Alliance Hunter New England Local Health District, New Lambton Heights, Australia
5 Hunter New England Local Health District, New Lambton Heights, Australia
6 La Trobe Rural Health School, College of Science, Health and Engineering, La Trobe University, Bendigo, VIC, Australia
7 Hunter Medical Research Institute, New Lambton Heights, Australia
8 Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
9 School of Life and Environmental Sciences, University of Sydney, New Lambton Heights, Australia
10 Diabetes Stream, Diabetes Alliance HNELHD, New Lambton Heights, Australia
11 The University of Sydney, Camperdown 2050, Australia
12 Endocrinology and Diabetes Service and Diabetes Alliance Hunter New England Local Health District, New Lambton Heights, Australia